CIMF
At the fore front of these advances is the discovery that 35%-55% of patients with CIMF harbor mutations in the Janus kinase 2 tyrosine kinase gene.
At the fore front of these advances is the discovery that 35%-55% of patients with <span class="disease" id="16951397-3-83-87">CIMF</span> harbor mutations in the <span class="gene" id="16951397-3-112-126">Janus kinase 2</span> tyrosine kinase gene.